{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:03:54Z","timestamp":1794672234957,"version":"4.9.1"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Hepatocellular carcinoma features extensive metabolic reprogramming. This includes alterations in major biochemical pathways such as glycolysis, the pentose phosphate pathway, amino acid metabolism and fatty acid metabolism. Moreover, there is a complex interplay among these altered pathways, particularly involving acetyl-CoA (coenzyme-A) metabolism and redox homeostasis, which in turn influences reprogramming of other metabolic pathways. Understanding these metabolic changes and their interactions with cellular signaling pathways offers potential strategies for the targeted treatment of hepatocellular carcinoma and improved patient outcomes. This review explores the specific metabolic alterations observed in hepatocellular carcinoma and highlights their roles in the progression of the disease.<\/jats:p>","DOI":"10.1038\/s12276-025-01415-2","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T01:01:42Z","timestamp":1740963702000},"page":"515-523","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":118,"title":["Metabolic reprogramming in hepatocellular carcinoma: mechanisms and therapeutic implications"],"prefix":"10.1038","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1211-8394","authenticated-orcid":false,"given":"Sujin","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"1415_CR1","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1101\/gad.278549.116","volume":"30","author":"TL Dayton","year":"2016","unstructured":"Dayton, T. L. et al. Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma. Genes Dev. 30, 1020\u20131033 (2016).","journal-title":"Genes Dev."},{"key":"1415_CR2","doi-asserted-by":"crossref","unstructured":"Ling, Z. N. et al. Amino acid metabolism in health and disease. Signal. Transduct. Target. Ther. 8, 345 (2023).","DOI":"10.1038\/s41392-023-01569-3"},{"key":"1415_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nrgastro.2017.32","volume":"14","author":"NL Gluchowski","year":"2017","unstructured":"Gluchowski, N. L., Becuwe, M., Walther, T. C. & Farese, R. V. Jr. Lipid droplets and liver disease: from basic biology to clinical implications. Nat. Rev. Gastroenterol. Hepatol. 14, 343\u2013355 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1415_CR4","doi-asserted-by":"crossref","unstructured":"Liu, X., Wang, H., Liang, X. & Roberts, M. S. in Liver Pathophysiology 391\u2013400 (Academic Press, 2017).","DOI":"10.1016\/B978-0-12-804274-8.00030-8"},{"key":"1415_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"M Josep","year":"2008","unstructured":"Josep, M. et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378\u2013390 (2008).","journal-title":"N. Engl. J. Med."},{"key":"1415_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"A-L Cheng","year":"2009","unstructured":"Cheng, A.-L. et al. Efficacy and safety of sorafenib in patients in the Asia\u2013Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25\u201334 (2009).","journal-title":"Lancet Oncol."},{"key":"1415_CR7","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1158\/1078-0432.CCR-15-1354","volume":"22","author":"M Ikeda","year":"2016","unstructured":"Ikeda, M. et al. Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 22, 1385\u20131394 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1415_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa, G. K. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379, 54\u201363 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1415_CR9","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389, 2492\u20132502 (2017).","journal-title":"Lancet"},{"key":"1415_CR10","doi-asserted-by":"publisher","unstructured":"Kumari R., Sahu M. K., Tripathy A., Uthansingh K. & Behera M. Hepatocellular carcinoma treatment: hurdles, advances and prospects. Hepat Oncol. https:\/\/doi.org\/10.2217\/hep-2018-0002 (2018).","DOI":"10.2217\/hep-2018-0002"},{"key":"1415_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers 7, 6 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1415_CR12","doi-asserted-by":"publisher","unstructured":"Vander Heiden M. G., Cantley L. C. & Thompson C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science https:\/\/doi.org\/10.1126\/science.1160809 (2009).","DOI":"10.1126\/science.1160809"},{"key":"1415_CR13","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/jcp.20166","volume":"202","author":"ML Macheda","year":"2005","unstructured":"Macheda, M. L., Rogers, S. & Best, J. D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol. 202, 654\u2013662 (2005).","journal-title":"J. Cell. Physiol."},{"key":"1415_CR14","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.2353\/ajpath.2009.080596","volume":"174","author":"T Amann","year":"2009","unstructured":"Amann, T. et al. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am. J. Pathol. 174, 1544\u20131552 (2009).","journal-title":"Am. J. Pathol."},{"key":"1415_CR15","doi-asserted-by":"publisher","first-page":"e0168907","DOI":"10.1371\/journal.pone.0168907","volume":"11","author":"HW Sun","year":"2016","unstructured":"Sun, H. W. et al. GLUT1 and ASCT2 as predictors for prognosis of hepatocellular carcinoma. PLoS ONE 11, e0168907 (2016).","journal-title":"PLoS ONE"},{"key":"1415_CR16","doi-asserted-by":"publisher","first-page":"68381","DOI":"10.18632\/oncotarget.20266","volume":"8","author":"YH Kim","year":"2017","unstructured":"Kim, Y. H. et al. SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma. Oncotarget 8, 68381\u201368392 (2017).","journal-title":"Oncotarget"},{"key":"1415_CR17","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1158\/0008-5472.CAN-13-0308","volume":"73","author":"Q Huang","year":"2013","unstructured":"Huang, Q. et al. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res. 73, 4992\u20135002 (2013).","journal-title":"Cancer Res."},{"key":"1415_CR18","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1038\/sj.onc.1209595","volume":"25","author":"RB Robey","year":"2006","unstructured":"Robey, R. B. & Hay, N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 25, 4683\u20134696 (2006).","journal-title":"Oncogene"},{"key":"1415_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02733-4","volume":"9","author":"D DeWaal","year":"2018","unstructured":"DeWaal, D. et al. Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. Nat. Commun. 9, 446 (2018).","journal-title":"Nat. Commun."},{"key":"1415_CR20","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s10620-014-3364-3","volume":"60","author":"G Guzman","year":"2015","unstructured":"Guzman, G. et al. Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma. Dig. Dis. Sci. 60, 420\u2013426 (2015).","journal-title":"Dig. Dis. Sci."},{"key":"1415_CR21","doi-asserted-by":"publisher","first-page":"5907","DOI":"10.1158\/0008-5472.CAN-19-1789","volume":"79","author":"S Xu","year":"2019","unstructured":"Xu, S. & Herschman, H. R. A tumor agnostic therapeutic strategy for hexokinase 1-null\/hexokinase 2-positive cancers. Cancer Res. 79, 5907\u20135914 (2019).","journal-title":"Cancer Res."},{"key":"1415_CR22","doi-asserted-by":"publisher","first-page":"17422","DOI":"10.1016\/S0021-9258(19)77853-3","volume":"263","author":"KK Arora","year":"1988","unstructured":"Arora, K. K. & Pedersen, P. L. Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP. J. Biol. Chem. 263, 17422\u201317428 (1988).","journal-title":"J. Biol. Chem."},{"key":"1415_CR23","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nature08697","volume":"463","author":"CJ David","year":"2010","unstructured":"David, C. J., Chen, M., Assanah, M., Canoll, P. & Manley, J. L. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463, 364\u2013368 (2010).","journal-title":"Nature"},{"key":"1415_CR24","doi-asserted-by":"crossref","unstructured":"Yu, G. et al. PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma. Mol. Cancer 14, 193 (2015).","DOI":"10.1186\/s12943-015-0462-6"},{"key":"1415_CR25","first-page":"2538","volume":"6","author":"Z Chen","year":"2015","unstructured":"Chen, Z. et al. Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma. Oncotarget 6, 2538\u20132548 (2015).","journal-title":"Oncotarget"},{"key":"1415_CR26","doi-asserted-by":"crossref","unstructured":"Faloppi, L. et al. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer 14, 110 (2014).","DOI":"10.1186\/1471-2407-14-110"},{"key":"1415_CR27","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1053\/j.gastro.2013.01.054","volume":"144","author":"A Budhu","year":"2013","unstructured":"Budhu, A. et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology 144, 1066\u20131075.e1061 (2013).","journal-title":"Gastroenterology"},{"key":"1415_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/hep.26350","volume":"58","author":"D Beyoglu","year":"2013","unstructured":"Beyoglu, D. et al. Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology 58, 229\u2013238 (2013).","journal-title":"Hepatology"},{"key":"1415_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110851","volume":"132","author":"S He","year":"2020","unstructured":"He, S. & Tang, S. WNT\/\u03b2-catenin signaling in the development of liver cancers. Biomed. Pharmacother. 132, 110851 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"1415_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3892\/ijo.2020.5152","volume":"58","author":"H Fan","year":"2021","unstructured":"Fan, H. et al. Critical role of mTOR in regulating aerobic glycolysis in carcinogenesis (review). Int. J. Oncol. 58, 9\u201319 (2021).","journal-title":"Int. J. Oncol."},{"key":"1415_CR31","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.2337\/db06-0200","volume":"55","author":"R Dentin","year":"2006","unstructured":"Dentin, R. et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob\/ob mice. Diabetes 55, 2159\u20132170 (2006).","journal-title":"Diabetes"},{"key":"1415_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98381-2","volume":"11","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. Glycolysis-related gene expression profiling serves as a novel prognosis risk predictor for human hepatocellular carcinoma. Sci. Rep. 11, 18875 (2021).","journal-title":"Sci. Rep."},{"key":"1415_CR33","doi-asserted-by":"crossref","unstructured":"Lee, N. C. W., Carella, M. A., Papa, S. & Bubici, C. High expression of glycolytic genes in cirrhosis correlates with the risk of developing liver cancer. Front. Cell. Dev. Biol. 6, 138 (2018).","DOI":"10.3389\/fcell.2018.00138"},{"key":"1415_CR34","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1111\/jcmm.14971","volume":"24","author":"M Li","year":"2020","unstructured":"Li, M. et al. Novel mitochondrion-targeting copper(II) complex induces HK2 malfunction and inhibits glycolysis via Drp1-mediating mitophagy in HCC. J. Cell. Mol. Med. 24, 3091\u20133107 (2020).","journal-title":"J. Cell. Mol. Med."},{"key":"1415_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114115","volume":"158","author":"M Li","year":"2023","unstructured":"Li, M., Zhang, A., Qi, X., Yu, R. & Li, J. A novel inhibitor of PGK1 suppresses the aerobic glycolysis and proliferation of hepatocellular carcinoma. Biomed. Pharmacother. 158, 114115 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"1415_CR36","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1080\/15548627.2022.2119353","volume":"19","author":"J Yao","year":"2023","unstructured":"Yao, J. et al. Isoginkgetin, a potential CDK6 inhibitor, suppresses SLC2A1\/GLUT1 enhancer activity to induce AMPK\u2013ULK1-mediated cytotoxic autophagy in hepatocellular carcinoma. Autophagy 19, 1221\u20131238 (2023).","journal-title":"Autophagy"},{"key":"1415_CR37","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1158\/0008-5472.CAN-20-0948","volume":"82","author":"WK Ma","year":"2022","unstructured":"Ma, W. K. et al. ASO-based PKM splice-switching therapy inhibits hepatocellular carcinoma growth. Cancer Res. 82, 900\u2013915 (2022).","journal-title":"Cancer Res."},{"key":"1415_CR38","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s43018-020-0086-7","volume":"1","author":"M Li","year":"2020","unstructured":"Li, M. et al. Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways. Nat. Cancer 1, 735\u2013747 (2020).","journal-title":"Nat. Cancer"},{"key":"1415_CR39","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1478-3231.2006.01243.x","volume":"26","author":"H Wada","year":"2006","unstructured":"Wada, H. et al. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int. 26, 414\u2013423 (2006).","journal-title":"Liver Int."},{"key":"1415_CR40","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/s42255-023-00863-2","volume":"5","author":"T TeSlaa","year":"2023","unstructured":"TeSlaa, T., Ralser, M., Fan, J. & Rabinowitz, J. D. The pentose phosphate pathway in health and disease. Nat. Metab. 5, 1275\u20131289 (2023).","journal-title":"Nat. Metab."},{"key":"1415_CR41","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.tibs.2014.06.005","volume":"39","author":"KC Patra","year":"2014","unstructured":"Patra, K. C. & Hay, N. The pentose phosphate pathway and cancer. Trends Biochem. Sci. 39, 347\u2013354 (2014).","journal-title":"Trends Biochem. Sci."},{"key":"1415_CR42","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S1369-5266(03)00039-6","volume":"6","author":"NJ Kruger","year":"2003","unstructured":"Kruger, N. J. & von Schaewen, A. The oxidative pentose phosphate pathway: structure and organisation. Curr. Opin. Plant Biol. 6, 236\u2013246 (2003).","journal-title":"Curr. Opin. Plant Biol."},{"key":"1415_CR43","doi-asserted-by":"publisher","first-page":"eaan2507","DOI":"10.1126\/science.aan2507","volume":"357","author":"M Uhlen","year":"2017","unstructured":"Uhlen, M. et al. A pathology atlas of the human cancer transcriptome. Science 357, eaan2507 (2017).","journal-title":"Science"},{"key":"1415_CR44","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jcmgh.2017.05.004","volume":"4","author":"ZC Nwosu","year":"2017","unstructured":"Nwosu, Z. C. et al. Identification of the consistently altered metabolic targets in human hepatocellular carcinoma. Cell. Mol. Gastroenterol. Hepatol. 4, 303\u2013323 e301 (2017).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"1415_CR45","doi-asserted-by":"crossref","unstructured":"Yin, X. et al. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway. J. Exp. Clin. Cancer Res. 36, 166 (2017).","DOI":"10.1186\/s13046-017-0637-7"},{"key":"1415_CR46","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/abbs\/gmy009","volume":"50","author":"M Lu","year":"2018","unstructured":"Lu, M. et al. Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial\u2013mesenchymal transition. Acta Biochim. Biophys. Sin. 50, 370\u2013380 (2018).","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"1415_CR47","doi-asserted-by":"publisher","first-page":"32375","DOI":"10.18632\/oncotarget.8632","volume":"7","author":"MA Kowalik","year":"2016","unstructured":"Kowalik, M. A. et al. Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis. Oncotarget 7, 32375\u201332393 (2016).","journal-title":"Oncotarget"},{"key":"1415_CR48","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/hep.25600","volume":"55","author":"M Evert","year":"2012","unstructured":"Evert, M. et al. V-AKT murine thymoma viral oncogene homolog\/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis. Hepatology 55, 1473\u20131484 (2012).","journal-title":"Hepatology"},{"key":"1415_CR49","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1158\/0008-5472.CAN-16-3538","volume":"77","author":"HKC Ngo","year":"2017","unstructured":"Ngo, H. K. C., Kim, D. H., Cha, Y. N., Na, H. K. & Surh, Y. J. Nrf2 mutagenic activation drives hepatocarcinogenesis. Cancer Res. 77, 4797\u20134808 (2017).","journal-title":"Cancer Res."},{"key":"1415_CR50","doi-asserted-by":"publisher","first-page":"E725","DOI":"10.1073\/pnas.1508779113","volume":"113","author":"IM Xu","year":"2016","unstructured":"Xu, I. M. et al. Transketolase counteracts oxidative stress to drive cancer development. Proc. Natl Acad. Sci. USA 113, E725\u2013E734 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1415_CR51","doi-asserted-by":"crossref","unstructured":"Qin, Z. et al. Transketolase (TKT) activity and nuclear localization promote hepatocellular carcinoma in a metabolic and a non-metabolic manner. J. Exp. Clin. Cancer Res. 38, 154 (2019).","DOI":"10.1186\/s13046-019-1131-1"},{"key":"1415_CR52","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.tibs.2010.05.003","volume":"35","author":"DR Wise","year":"2010","unstructured":"Wise, D. R. & Thompson, C. B. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci. 35, 427\u2013433 (2010).","journal-title":"Trends Biochem. Sci."},{"key":"1415_CR53","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1146\/annurev-bioeng-071516-044546","volume":"19","author":"L Yang","year":"2017","unstructured":"Yang, L., Venneti, S. & Nagrath, D. Glutaminolysis: a hallmark of cancer metabolism. Annu. Rev. Biomed. Eng. 19, 163\u2013194 (2017).","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"1415_CR54","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.trecan.2021.04.003","volume":"7","author":"WH Yang","year":"2021","unstructured":"Yang, W. H., Qiu, Y., Stamatatos, O., Janowitz, T. & Lukey, M. J. Enhancing the efficacy of glutamine metabolism inhibitors in cancer therapy. Trends Cancer 7, 790\u2013804 (2021).","journal-title":"Trends Cancer"},{"key":"1415_CR55","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1016\/j.celrep.2015.10.045","volume":"13","author":"E Bjornson","year":"2015","unstructured":"Bjornson, E. et al. Stratification of hepatocellular carcinoma patients based on acetate utilization. Cell Rep. 13, 2014\u20132026 (2015).","journal-title":"Cell Rep."},{"key":"1415_CR56","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","volume":"7","author":"RJ DeBerardinis","year":"2008","unstructured":"DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G. & Thompson, C. B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 11\u201320 (2008).","journal-title":"Cell Metab."},{"key":"1415_CR57","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.gendis.2020.01.016","volume":"7","author":"WW Zhu","year":"2020","unstructured":"Zhu, W. W. et al. The fuel and engine: the roles of reprogrammed metabolism in metastasis of primary liver cancer. Genes Dis. 7, 299\u2013307 (2020).","journal-title":"Genes Dis."},{"key":"1415_CR58","doi-asserted-by":"publisher","first-page":"7619","DOI":"10.18632\/oncotarget.3196","volume":"6","author":"D Yu","year":"2015","unstructured":"Yu, D. et al. Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma. Oncotarget 6, 7619\u20137631 (2015).","journal-title":"Oncotarget"},{"key":"1415_CR59","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s12072-010-9230-2","volume":"5","author":"J Long","year":"2011","unstructured":"Long, J. et al. Expression level of glutamine synthetase is increased in hepatocellular carcinoma and liver tissue with cirrhosis and chronic hepatitis B. Hepatol. Int. 5, 698\u2013706 (2011).","journal-title":"Hepatol. Int."},{"key":"1415_CR60","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/hepr.13433","volume":"50","author":"P Liu","year":"2020","unstructured":"Liu, P. et al. Glutamine synthetase promotes tumor invasion in hepatocellular carcinoma through mediating epithelial\u2013mesenchymal transition. Hepatol. Res. 50, 246\u2013257 (2020).","journal-title":"Hepatol. Res."},{"key":"1415_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.174","volume":"50","author":"BH Sohn","year":"2018","unstructured":"Sohn, B. H., Park, I. Y., Shin, J. H., Yim, S. Y. & Lee, J. S. Glutamine synthetase mediates sorafenib sensitivity in \u03b2-catenin-active hepatocellular carcinoma cells. Exp. Mol. Med. 50, e421 (2018).","journal-title":"Exp. Mol. Med."},{"key":"1415_CR62","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.humpath.2015.10.014","volume":"50","author":"H Tsujikawa","year":"2016","unstructured":"Tsujikawa, H. et al. Immunohistochemical molecular analysis indicates hepatocellular carcinoma subgroups that reflect tumor aggressiveness. Hum. Pathol. 50, 24\u201333 (2016).","journal-title":"Hum. Pathol."},{"key":"1415_CR63","unstructured":"Zhang, B. et al. Glutamine synthetase predicts adjuvant TACE response in hepatocellular carcinoma. Int. J. Clin. Exp. Med. 8, 20722\u201320731 (2015)."},{"key":"1415_CR64","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.cmet.2019.01.002","volume":"29","author":"AO Adebayo Michael","year":"2019","unstructured":"Adebayo Michael, A. O. et al. Inhibiting glutamine-dependent mTORC1 activation ameliorates liver cancers driven by \u03b2-catenin mutations. Cell Metab. 29, 1135\u20131150.e1136 (2019).","journal-title":"Cell Metab."},{"key":"1415_CR65","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/hep.30421","volume":"69","author":"YS Wang","year":"2019","unstructured":"Wang, Y. S. et al. Sirtuin 4 depletion promotes hepatocellular carcinoma tumorigenesis through regulating adenosine-monophosphate-activated protein kinase alpha\/mammalian target of rapamycin axis in mice. Hepatology 69, 1614\u20131631 (2019).","journal-title":"Hepatology"},{"key":"1415_CR66","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41392-021-00801-2","volume":"6","author":"Y Wei","year":"2021","unstructured":"Wei, Y. et al. An RNA\u2013RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity. Signal. Transduct. Target. Ther. 6, 421 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1415_CR67","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1080\/15548627.2019.1580105","volume":"15","author":"X Huang","year":"2019","unstructured":"Huang, X., Gan, G., Wang, X., Xu, T. & Xie, W. The HGF\u2013MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance. Autophagy 15, 1258\u20131279 (2019).","journal-title":"Autophagy"},{"key":"1415_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4254\/wjh.v9.i1.1","volume":"9","author":"AI Fitian","year":"2017","unstructured":"Fitian, A. I. & Cabrera, R. Disease monitoring of hepatocellular carcinoma through metabolomics. World J. Hepatol. 9, 1\u201317 (2017).","journal-title":"World J. Hepatol."},{"key":"1415_CR69","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canlet.2019.09.010","volume":"466","author":"H Guo","year":"2019","unstructured":"Guo, H. et al. NRF2 SUMOylation promotes de novo serine synthesis and maintains HCC tumorigenesis. Cancer Lett. 466, 39\u201348 (2019).","journal-title":"Cancer Lett."},{"key":"1415_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36708-5","volume":"14","author":"K Wang","year":"2023","unstructured":"Wang, K. et al. PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma. Nat. Commun. 14, 1011 (2023).","journal-title":"Nat. Commun."},{"key":"1415_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12606-7","volume":"10","author":"L Wei","year":"2019","unstructured":"Wei, L. et al. Genome-wide CRISPR\u2013Cas9 library screening identified PHGDH as a critical driver for sorafenib resistance in HCC. Nat. Commun. 10, 4681 (2019).","journal-title":"Nat. Commun."},{"key":"1415_CR72","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/bmb.2003.494031050249","volume":"31","author":"M Watford","year":"2006","unstructured":"Watford, M. The urea cycle: teaching intermediary metabolism in a physiological setting. Biochem. Mol. Biol. Educ. 31, 289\u2013297 (2006).","journal-title":"Biochem. Mol. Biol. Educ."},{"key":"1415_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/gastro\/goaa066","volume":"9","author":"DG Tenen","year":"2021","unstructured":"Tenen, D. G., Chai, L. & Tan, J. L. Metabolic alterations and vulnerabilities in hepatocellular carcinoma. Gastroenterol. Rep. 9, 1\u201313 (2021).","journal-title":"Gastroenterol. Rep."},{"key":"1415_CR74","doi-asserted-by":"crossref","unstructured":"McAlpine, J. A., Lu, H. T., Wu, K. C., Knowles, S. K. & Thomson, J. A. Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy. BMC Cancer 14, 621 (2014).","DOI":"10.1186\/1471-2407-14-621"},{"key":"1415_CR75","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1016\/j.molcel.2021.08.005","volume":"81","author":"E Hajaj","year":"2021","unstructured":"Hajaj, E., Sciacovelli, M., Frezza, C. & Erez, A. The context-specific roles of urea cycle enzymes in tumorigenesis. Mol. Cell 81, 3749\u20133759 (2021).","journal-title":"Mol. Cell"},{"key":"1415_CR76","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/abbs\/gmz005","volume":"51","author":"X Tao","year":"2019","unstructured":"Tao, X. et al. Argininosuccinate synthase 1 suppresses cancer cell invasion by inhibiting STAT3 pathway in hepatocellular carcinoma. Acta Biochim. Biophys. Sin. 51, 263\u2013276 (2019).","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"1415_CR77","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/j.1476-5381.2009.00291.x","volume":"158","author":"M Munder","year":"2009","unstructured":"Munder, M. Arginase: an emerging key player in the mammalian immune system. Br. J. Pharmacol. 158, 638\u2013651 (2009).","journal-title":"Br. J. Pharmacol."},{"key":"1415_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112840","volume":"149","author":"F Niu","year":"2022","unstructured":"Niu, F. et al. Arginase: an emerging and promising therapeutic target for cancer treatment. Biomed. Pharmacother. 149, 112840 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"1415_CR79","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","volume":"18","author":"D Mossmann","year":"2018","unstructured":"Mossmann, D., Park, S. & Hall, M. N. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat. Rev. Cancer 18, 744\u2013757 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"1415_CR80","doi-asserted-by":"publisher","first-page":"8339","DOI":"10.18632\/oncotarget.3234","volume":"6","author":"T Kishikawa","year":"2015","unstructured":"Kishikawa, T. et al. Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine. Oncotarget 6, 8339\u20138352 (2015).","journal-title":"Oncotarget"},{"key":"1415_CR81","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.cmet.2022.06.010","volume":"34","author":"R Missiaen","year":"2022","unstructured":"Missiaen, R. et al. GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment. Cell Metab. 34, 1151\u20131167.e1157 (2022).","journal-title":"Cell Metab"},{"key":"1415_CR82","doi-asserted-by":"publisher","first-page":"5068","DOI":"10.1016\/j.cell.2023.09.011","volume":"186","author":"D Mossmann","year":"2023","unstructured":"Mossmann, D. et al. Arginine reprograms metabolism in liver cancer via RBM39. Cell 186, 5068\u20135083.e5023 (2023).","journal-title":"Cell"},{"key":"1415_CR83","doi-asserted-by":"publisher","unstructured":"Richards, N. G. & Schuster, S. M. Mechanistic issues in asparagine synthetase catalysis. Adv. Enzymol. Relat. Areas Mol. Biol. https:\/\/doi.org\/10.1002\/9780470123188.ch5 (1998).","DOI":"10.1002\/9780470123188.ch5"},{"key":"1415_CR84","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/bjc.2013.293","volume":"109","author":"B Zhang","year":"2013","unstructured":"Zhang, B. et al. Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma. Br. J. Cancer 109, 14\u201323 (2013).","journal-title":"Br. J. Cancer"},{"key":"1415_CR85","doi-asserted-by":"publisher","first-page":"e0153358","DOI":"10.1371\/journal.pone.0153358","volume":"11","author":"A Laemmle","year":"2016","unstructured":"Laemmle, A. et al. Frequency and pathophysiology of acute liver failure in ornithine transcarbamylase deficiency (OTCD). PLoS ONE 11, e0153358 (2016).","journal-title":"PLoS ONE"},{"key":"1415_CR86","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ymgme.2017.02.011","volume":"120","author":"L Wang","year":"2017","unstructured":"Wang, L. et al. AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice. Mol. Genet. Metab. 120, 299\u2013305 (2017).","journal-title":"Mol. Genet. Metab."},{"key":"1415_CR87","doi-asserted-by":"publisher","first-page":"6747","DOI":"10.1038\/s41388-020-01480-z","volume":"39","author":"H Peng","year":"2020","unstructured":"Peng, H., Wang, Y. & Luo, W. Multifaceted role of branched-chain amino acid metabolism in cancer. Oncogene 39, 6747\u20136756 (2020).","journal-title":"Oncogene"},{"key":"1415_CR88","doi-asserted-by":"publisher","unstructured":"Harper, E., Miller, R. H. & Block, K. P. Branched-chain amino acid metabolism. Metabolism https:\/\/doi.org\/10.1146\/annurev.nu.04.070184.002205 (1984).","DOI":"10.1146\/annurev.nu.04.070184.002205"},{"key":"1415_CR89","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature22314","volume":"545","author":"A Hattori","year":"2017","unstructured":"Hattori, A. et al. Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia. Nature 545, 500\u2013504 (2017).","journal-title":"Nature"},{"key":"1415_CR90","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41556-019-0455-6","volume":"22","author":"JT Li","year":"2020","unstructured":"Li, J. T. et al. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma. Nat. Cell Biol. 22, 167\u2013174 (2020).","journal-title":"Nat. Cell Biol."},{"key":"1415_CR91","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1126\/science.aaf5171","volume":"353","author":"JR Mayers","year":"2016","unstructured":"Mayers, J. R. et al. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science 353, 1161\u20131165 (2016).","journal-title":"Science"},{"key":"1415_CR92","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/ajcn\/68.1.72","volume":"68","author":"A Suryawan","year":"1998","unstructured":"Suryawan, A. et al. A molecular model of human branched-chain amino acid metabolism. Am. J. Clin. Nutr. 68, 72\u201381 (1998).","journal-title":"Am. J. Clin. Nutr."},{"key":"1415_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111691","volume":"41","author":"D Yang","year":"2022","unstructured":"Yang, D. et al. Branched-chain amino acid catabolism breaks glutamine addiction to sustain hepatocellular carcinoma progression. Cell Rep. 41, 111691 (2022).","journal-title":"Cell Rep."},{"key":"1415_CR94","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.3892\/ol.2016.4969","volume":"12","author":"M Xu","year":"2016","unstructured":"Xu, M. et al. BCAT1 promotes tumor cell migration and invasion in hepatocellular carcinoma. Oncol. Lett. 12, 2648\u20132656 (2016).","journal-title":"Oncol. Lett."},{"key":"1415_CR95","doi-asserted-by":"publisher","unstructured":"Takegoshi, K. et al. Branched-chain amino acids prevent hepatic fibrosis and development of hepatocellular carcinoma in a non-alcoholic steatohepatitis mouse model. Oncotarget https:\/\/doi.org\/10.18632\/oncotarget.15304 (2017).","DOI":"10.18632\/oncotarget.15304"},{"key":"1415_CR96","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.clnu.2018.12.022","volume":"38","author":"M Plauth","year":"2019","unstructured":"Plauth, M. et al. ESPEN guideline on clinical nutrition in liver disease. Clin. Nutr. 38, 485\u2013521 (2019).","journal-title":"Clin. Nutr."},{"key":"1415_CR97","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1245\/s10434-016-5348-3","volume":"23","author":"Y Kikuchi","year":"2016","unstructured":"Kikuchi, Y. et al. A randomized clinical trial of preoperative administration of branched-chain amino acids to prevent postoperative ascites in patients with liver resection for hepatocellular carcinoma. Ann. Surg. Oncol. 23, 3727\u20133735 (2016).","journal-title":"Ann. Surg. Oncol."},{"key":"1415_CR98","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/j.1349-7006.2009.01402.x","volume":"101","author":"J Iwasa","year":"2010","unstructured":"Iwasa, J. et al. Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL\/KsJ-db\/db mice. Cancer Sci. 101, 460\u2013467 (2010).","journal-title":"Cancer Sci."},{"key":"1415_CR99","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00535-009-0031-0","volume":"44","author":"H Yoshiji","year":"2009","unstructured":"Yoshiji, H. et al. Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. J. Gastroenterol. 44, 483\u2013491 (2009).","journal-title":"J. Gastroenterol."},{"key":"1415_CR100","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.cmet.2018.12.020","volume":"29","author":"RE Ericksen","year":"2019","unstructured":"Ericksen, R. E. et al. Loss of BCAA catabolism during carcinogenesis enhances mTORC1 activity and promotes tumor development and progression. Cell Metab. 29, 1151\u20131165e1156 (2019).","journal-title":"Cell Metab."},{"key":"1415_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14689","volume":"8","author":"ME Nelson","year":"2017","unstructured":"Nelson, M. E. et al. Inhibition of hepatic lipogenesis enhances liver tumorigenesis by increasing antioxidant defence and promoting cell survival. Nat. Commun. 8, 14689 (2017).","journal-title":"Nat. Commun."},{"key":"1415_CR102","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41418-019-0399-1","volume":"27","author":"Q Gao","year":"2020","unstructured":"Gao, Q. et al. SLC27A5 deficiency activates NRF2\/TXNRD1 pathway by increased lipid peroxidation in HCC. Cell Death Differ. 27, 1086\u20131104 (2020).","journal-title":"Cell Death Differ."},{"key":"1415_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100479","volume":"4","author":"B Paul","year":"2022","unstructured":"Paul, B., Lewinska, M. & Andersen, J. B. Lipid alterations in chronic liver disease and liver cancer. JHEP Rep. 4, 100479 (2022).","journal-title":"JHEP Rep."},{"key":"1415_CR104","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","volume":"18","author":"E Currie","year":"2013","unstructured":"Currie, E., Schulze, A., Zechner, R., Walther, T. C. & Farese, R. V. Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 18, 153\u2013161 (2013).","journal-title":"Cell Metab."},{"key":"1415_CR105","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1053\/j.gastro.2010.12.006","volume":"140","author":"DF Calvisi","year":"2011","unstructured":"Calvisi, D. F. et al. Increased lipogenesis, induced by AKT\u2013mTORC1\u2013RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 140, 1071\u20131083 (2011).","journal-title":"Gastroenterology"},{"key":"1415_CR106","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1002\/hep.28415","volume":"63","author":"MD Wang","year":"2016","unstructured":"Wang, M. D. et al. Acetyl-coenzyme A carboxylase alpha promotion of glucose-mediated fatty acid synthesis enhances survival of hepatocellular carcinoma in mice and patients. Hepatology 63, 1272\u20131286 (2016).","journal-title":"Hepatology"},{"key":"1415_CR107","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jhep.2015.10.004","volume":"64","author":"L Li","year":"2016","unstructured":"Li, L. et al. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans. J. Hepatol. 64, 333\u2013341 (2016).","journal-title":"J. Hepatol."},{"key":"1415_CR108","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/nm.3372","volume":"19","author":"MD Fullerton","year":"2013","unstructured":"Fullerton, M. D. et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat. Med. 19, 1649\u20131654 (2013).","journal-title":"Nat. Med."},{"key":"1415_CR109","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.cmet.2018.08.020","volume":"29","author":"JSV Lally","year":"2019","unstructured":"Lally, J. S. V. et al. Inhibition of acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma. Cell Metab. 29, 174\u2013182.e175 (2019).","journal-title":"Cell Metab."},{"key":"1415_CR110","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/hep.32359","volume":"76","author":"H Wang","year":"2022","unstructured":"Wang, H. et al. Therapeutic efficacy of FASN inhibition in preclinical models of HCC. Hepatology 76, 951\u2013966 (2022).","journal-title":"Hepatology"},{"key":"1415_CR111","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cmet.2012.09.002","volume":"16","author":"W Shao","year":"2012","unstructured":"Shao, W. & Espenshade, P. J. Expanding roles for SREBP in metabolism. Cell Metab. 16, 414\u2013419 (2012).","journal-title":"Cell Metab."},{"key":"1415_CR112","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.3390\/ijms15057124","volume":"15","author":"C Li","year":"2014","unstructured":"Li, C. et al. SREBP-1 has a prognostic role and contributes to invasion and metastasis in human hepatocellular carcinoma. Int. J. Mol. Sci. 15, 7124\u20137138 (2014).","journal-title":"Int. J. Mol. Sci."},{"key":"1415_CR113","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1158\/0008-5472.CAN-20-3944","volume":"81","author":"APY Ma","year":"2021","unstructured":"Ma, A. P. Y. et al. Suppression of ACADM-mediated fatty acid oxidation promotes hepatocellular carcinoma via aberrant CAV1\/SREBP1 signaling. Cancer Res. 81, 3679\u20133692 (2021).","journal-title":"Cancer Res."},{"key":"1415_CR114","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jhep.2008.07.036","volume":"50","author":"T Yamashita","year":"2009","unstructured":"Yamashita, T. et al. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J. Hepatol. 50, 100\u2013110 (2009).","journal-title":"J. Hepatol."},{"key":"1415_CR115","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.cmet.2008.07.007","volume":"8","author":"T Porstmann","year":"2008","unstructured":"Porstmann, T. et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 8, 224\u2013236 (2008).","journal-title":"Cell Metab."},{"key":"1415_CR116","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/onc.2015.123","volume":"35","author":"S Li","year":"2016","unstructured":"Li, S., Oh, Y. T., Yue, P., Khuri, F. R. & Sun, S. Y. Inhibition of mTOR complex 2 induces GSK3\/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells. Oncogene 35, 642\u2013650 (2016).","journal-title":"Oncogene"},{"key":"1415_CR117","doi-asserted-by":"publisher","first-page":"16184","DOI":"10.1073\/pnas.1213343109","volume":"109","author":"JL Owen","year":"2012","unstructured":"Owen, J. L. et al. Insulin stimulation of SREBP-1c processing in transgenic rat hepatocytes requires p70 S6-kinase. Proc. Natl Acad. Sci. USA 109, 16184\u201316189 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1415_CR118","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.cmet.2012.03.015","volume":"15","author":"A Hagiwara","year":"2012","unstructured":"Hagiwara, A. et al. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab. 15, 725\u2013738 (2012).","journal-title":"Cell Metab."},{"key":"1415_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1828-2","volume":"10","author":"T Li","year":"2019","unstructured":"Li, T. et al. mTOR direct crosstalk with STAT5 promotes de novo lipid synthesis and induces hepatocellular carcinoma. Cell Death Dis. 10, 619 (2019).","journal-title":"Cell Death Dis."},{"key":"1415_CR120","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cmet.2011.06.002","volume":"14","author":"JL Yecies","year":"2011","unstructured":"Yecies, J. L. et al. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab. 14, 21\u201332 (2011).","journal-title":"Cell Metab."},{"key":"1415_CR121","doi-asserted-by":"publisher","unstructured":"Suchithra, M. et al. Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci. Signal. https:\/\/doi.org\/10.1126\/scisignal.200273 (2012).","DOI":"10.1126\/scisignal.200273"},{"key":"1415_CR122","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-020-2183-2","volume":"580","author":"D Xu","year":"2020","unstructured":"Xu, D. et al. The gluconeogenic enzyme PCK1 phosphorylates INSIG1\/2 for lipogenesis. Nature 580, 530\u2013535 (2020).","journal-title":"Nature"},{"key":"1415_CR123","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.ccell.2017.11.011","volume":"32","author":"Y Guri","year":"2017","unstructured":"Guri, Y. et al. mTORC2 promotes tumorigenesis via lipid synthesis. Cancer Cell 32, 807\u2013823.e812 (2017).","journal-title":"Cancer Cell"},{"key":"1415_CR124","doi-asserted-by":"publisher","unstructured":"Kerner, J. & Hoppel, C. Fatty acid import into mitochondria. Biochim. Biophys. Acta https:\/\/doi.org\/10.1016\/S1388-1981(00)00044-5 (2000).","DOI":"10.1016\/S1388-1981(00)00044-5"},{"key":"1415_CR125","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1365-2362.2008.01936.x","volume":"38","author":"G Serviddio","year":"2008","unstructured":"Serviddio, G. et al. Alterations of hepatic ATP homeostasis and respiratory chain during development of non-alcoholic steatohepatitis in a rodent model. Eur. J. Clin. Invest. 38, 245\u2013252 (2008).","journal-title":"Eur. J. Clin. Invest."},{"key":"1415_CR126","doi-asserted-by":"publisher","first-page":"e24084","DOI":"10.1371\/journal.pone.0024084","volume":"6","author":"G Serviddio","year":"2011","unstructured":"Serviddio, G. et al. Oxidation of hepatic carnitine palmitoyl transferase-I (CPT-I) impairs fatty acid \u03b2-oxidation in rats fed a methionine-choline deficient diet. PLoS ONE 6, e24084 (2011).","journal-title":"PLoS ONE"},{"key":"1415_CR127","doi-asserted-by":"publisher","unstructured":"Liu, Y. et al. CPT1A loss disrupts BCAA metabolism to confer therapeutic vulnerability in TP53-mutated liver cancer. Cancer Lett. https:\/\/doi.org\/10.1016\/j.canlet.2024.217006 (2024).","DOI":"10.1016\/j.canlet.2024.217006"},{"key":"1415_CR128","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1136\/gutjnl-2017-315193","volume":"67","author":"N Fujiwara","year":"2018","unstructured":"Fujiwara, N. et al. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. Gut 67, 1493\u20131504 (2018).","journal-title":"Gut"},{"key":"1415_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/srep20299","volume":"6","author":"J Yaligar","year":"2016","unstructured":"Yaligar, J. et al. Longitudinal metabolic imaging of hepatocellular carcinoma in transgenic mouse models identifies acylcarnitine as a potential biomarker for early detection. Sci. Rep. 6, 20299 (2016).","journal-title":"Sci. Rep."},{"key":"1415_CR130","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.celrep.2014.08.028","volume":"8","author":"D Huang","year":"2014","unstructured":"Huang, D. et al. HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression. Cell Rep. 8, 1930\u20131942 (2014).","journal-title":"Cell Rep."},{"key":"1415_CR131","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.tibs.2017.11.004","volume":"43","author":"S Sivanand","year":"2018","unstructured":"Sivanand, S., Viney, I. & Wellen, K. E. Spatiotemporal control of acetyl-CoA metabolism in chromatin regulation. Trends Biochem. Sci. 43, 61\u201374 (2018).","journal-title":"Trends Biochem. Sci."},{"key":"1415_CR132","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cmet.2015.05.014","volume":"21","author":"F Pietrocola","year":"2015","unstructured":"Pietrocola, F., Galluzzi, L., Bravo-San Pedro, J. M., Madeo, F. & Kroemer, G. Acetyl coenzyme A: a central metabolite and second messenger. Cell Metab. 21, 805\u2013821 (2015).","journal-title":"Cell Metab."},{"key":"1415_CR133","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1016\/j.molcel.2022.10.027","volume":"82","author":"S Park","year":"2022","unstructured":"Park, S. et al. Transcription factors TEAD2 and E2A globally repress acetyl-CoA synthesis to promote tumorigenesis. Mol. Cell 82, 4246\u20134261.e4211 (2022).","journal-title":"Mol. Cell"},{"key":"1415_CR134","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1007\/s12072-009-9158-6","volume":"3","author":"P Muriel","year":"2009","unstructured":"Muriel, P. Role of free radicals in liver diseases. Hepatol. Int. 3, 526\u2013536 (2009).","journal-title":"Hepatol. Int."},{"key":"1415_CR135","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.arr.2012.10.004","volume":"12","author":"V Sosa","year":"2013","unstructured":"Sosa, V. et al. Oxidative stress and cancer: an overview. Ageing Res. Rev. 12, 376\u2013390 (2013).","journal-title":"Ageing Res. Rev."},{"key":"1415_CR136","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ccell.2020.05.018","volume":"38","author":"Y Kudo","year":"2020","unstructured":"Kudo, Y. et al. PKC\u03bb\/\u03b9 loss induces autophagy, oxidative phosphorylation, and NRF2 to promote liver cancer progression. Cancer Cell 38, 247\u2013262.e211 (2020).","journal-title":"Cancer Cell"},{"key":"1415_CR137","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ebiom.2018.11.063","volume":"39","author":"B Li","year":"2019","unstructured":"Li, B. et al. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt\/beta-catenin pathway. EBioMedicine 39, 239\u2013254 (2019).","journal-title":"EBioMedicine"},{"key":"1415_CR138","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1158\/1541-7786.MCR-17-0061","volume":"15","author":"MJ Kim","year":"2017","unstructured":"Kim, M. J. et al. PPAR\u03b4 reprograms glutamine metabolism in sorafenib-resistant HCC. Mol. Cancer Res. 15, 1230\u20131242 (2017).","journal-title":"Mol. Cancer Res."},{"key":"1415_CR139","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00535-012-0739-0","volume":"48","author":"S Tanaka","year":"2013","unstructured":"Tanaka, S. et al. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. J. Gastroenterol. 48, 1249\u20131258 (2013).","journal-title":"J. Gastroenterol"},{"key":"1415_CR140","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2169\/internalmedicine.56.7002","volume":"56","author":"Y Shimomura","year":"2017","unstructured":"Shimomura, Y. et al. The serum oxidative\/anti-oxidative stress balance becomes dysregulated in patients with non-alcoholic steatohepatitis associated with hepatocellular carcinoma. Intern. Med. 56, 243\u2013251 (2017).","journal-title":"Intern. Med."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01415-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01415-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01415-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T03:41:40Z","timestamp":1743738100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01415-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":140,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["1415"],"URL":"https:\/\/doi.org\/10.1038\/s12276-025-01415-2","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}